| Affiliation: | 1. Section of Cardiovascular Medicine, VA Connecticut, West Haven, Connecticut;2. Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut;3. Western University of Health Sciences, Pomona, California;4. Veterans Affairs Medical Center, Minneapolis, Minnesota;5. University of Minnesota, Minneapolis, Minnesota;6. CCRE Therapeutics, Monash University, Melbourne, Australia;7. Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts;8. British Heart Foundation Glasgow Cardiovascular Research Center, Glasgow, United Kingdom;9. RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, South Carolina;10. Université Paris 6; Pitie Salpetriere Hospital, Paris, France;11. Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada;12. Washington VAMC and Georgetown University, Washington, DC |
| Abstract: | BackgroundThe prognostic merit of insulin-like growth factor-binding protein 7 (IGFBP7) is unknown in heart failure and preserved ejection fraction (HFpEF).Methods and ResultsBaseline IGFBP7 (BL-IGFBP7; n?=?302) and 6-month change (Δ; n?=?293) were evaluated in the Irbesartan in Heart Failure and Preserved Ejection Fraction (I-PRESERVE) trial. Primary outcome was all-cause mortality or cardiovascular hospitalization with median follow-up of 3.6 years; secondary outcomes included HF events. Median BL-IGFBP7 concentration was 218?ng/mL. BL-IGFBP7 was significantly correlated with age (R2?=?0.13; P?R2?=?0.22; P?R2?=?0.14; P?P?P?P?R2?=?0.09; P?=?.002). ΔIGFBP7 was not independently associated with outcome.ConclusionsHigher concentrations of IGFBP7 were associated with increased risk of cardiovascular events, but after multivariable adjustment this association was no longer present. Further studies of IGFBP7 are needed to elucidate its mechanism. |
